查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2000677

生物製药契约製造市场：2026-2032年全球市场预测（依服务类型、产品类型、生产阶段、应用和组织规模划分）

Biopharmaceuticals Contract Manufacturing Market by Service Type, Product Type, Production Stage, Application, Organisation Size - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，生物製药契约製造市场价值将达到 231.1 亿美元，到 2026 年将成长至 252.3 亿美元，到 2032 年将达到 437.9 亿美元，复合年增长率为 9.55%。

主要市场统计数据
基准年 2025 231.1亿美元
预计年份：2026年 252.3亿美元
预测年份 2032 437.9亿美元
复合年增长率 (%) 9.55%

生物製药契约製造领域的开创性进步，为下一代治疗方法和更优越的供应链的开发提供了可能。

生物製药契约製造的模式已从单纯的辅助服务模式演变为加速创新和缩短产品上市时间的策略驱动力。随着治疗方法日益复杂，从单株抗体到先进的细胞和基因疗法，外包合作伙伴不再只是服务供应商，而是製剂开发、製程优化和法规遵循至关重要的合作者。这一转变的驱动力源于先进技术平台的整合、严格的品质要求以及对整个开发流程中营运柔软性的日益增长的需求。

在技​​术进步和策略伙伴关係推动产业发生前所未有的变革之际，生物製药契约製造领域模式转移。

生物製药契约製造产业正经历重大变革，其驱动力来自技术突破、策略联盟以及监管模式的转变。一次性技术和连续生产方式正在取代传统的不銹钢系统，从而提升生产线的灵活性并缩短前置作业时间。人工智慧 (AI) 和先进的分析技术正被整合到品管流程中，增强预测性维护能力，并确保批次间的一致性。

对 2025 年美国关税对生物製药契约製造。

美国将于2025年实施的新关税正在对整个全球生物製药契约製造供应链产生连锁反应。对来自受影响地区的原料和关键试剂征收更高的关税，推高了投入成本，并挤压了利润空间。为了应对这项挑战，契约製造生产商正在透过审查供应商组合、探索近岸外包方案以及重新谈判长期供应合约来降低波动风险。

按服务/产品类型、生产阶段、应用和组织规模对生物製药契约製造进行细分的见解。

对服务类型、产品类型、生产阶段、应用领域和组织规模的详细分析揭示了契约製造领域中存在的微妙机会和挑战。分析和品管测试仍然至关重要，但高通量、多属性分析方法在加速决策方面变得日益重要。生物製药製造服务正在不断发展，以处理日益复杂的分子，同时製程开发和优化工作也以平行工作流程的形式进行，加速了从实验室规模到中试生产的过渡。

了解美洲、欧洲、中东和非洲以及亚太地区生物製药契约製造的区域趋势。

区域趋势在塑造外包策略和成本结构方面发挥着至关重要的作用。美洲地区拥有强大的契约製造，这得益于其完善的契约製造组织（CMO）生态系统、监管专业知识和成熟的物流网络。同时，欧洲、中东和非洲则受益于丰富的专业科研人才、特定市场的优惠税收政策以及促进早期生物製程创新的产学研合作传统。

寻找塑造全球生物製药契约製造未来发展的关键创新者和策略合作伙伴。

领先的契约製造公司凭藉技术优势、生产规模以及与大型生物製药公司和新兴生物技术创新者的策略合作伙伴关係脱颖而出。一些供应商正大力投资一次性生物反应器系统和连续层析法，而另一些供应商则透过多属性质谱和自动化采样技术来增强其分析测试能力。

为行业领导者提供切实可行的策略，以推动生物製药契约製造製造业在不断发展的环境中实现成长和卓越营运。

行业领导者必须采取多管齐下的策略，以确保韧性并推动成长。投资于整合即时製程监控和预测分析的数位化平台，可以提高决策效率并降低批次失败的风险。结合模组化设施和一次性技术的灵活生产网络，能够提供应对不同临床阶段和治疗方法需求波动所需的敏捷性。

采用严谨的方法论和创新的调查方法，揭示了生物製药契约製造研究中的重要见解。

本分析采用混合调查方法，结合了严谨的二手资料研究和质性访谈。透过对监管指南、行业白皮书和公司特定出版物的深入考察，我们对技术趋势和政策变化有了基本的了解。二手资料来源的可靠性经过严格审查，并与近期同行评审的学术期刊进行交叉核对，以确保事实的准确性。

总结关键发现并整合见解，以指导生物製药契约製造生态系统中的策略决策者。

在整合研究结果的过程中，涌现出几个核心主题：技术敏捷性的重要性日益凸显、策略伙伴关係的关键作用，以及在贸易政策波动的情况下供应链韧性的必要性。这些见解强调了契约製造製造商亟需超越传统的产能提供模式，并转型为一体化的创新合作伙伴。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：生物製药契约製造市场：依服务类型划分

  • 分析和品管测试
  • 生技药品生产服务
  • 製程开发与最佳化

第九章：生物製药契约製造市场：依产品类型划分

  • 细胞和基因治疗
    • CAR-T疗法
    • 基因编辑疗法
  • 单株抗体
  • 重组蛋白
    • 酵素
    • 荷尔蒙
  • 疫苗
    • 药效疫苗
    • 蛋白质次单元疫苗
    • 病毒载体疫苗

第十章：依生产阶段分類的生物製药契约製造市场

  • 临床
    • 第一阶段
    • 第二阶段
    • 第三阶段
  • 商业的

第十一章：生物製药契约製造市场：依应用领域划分

  • 自体免疫疾病
  • 循环系统
  • 感染疾病
    • 细菌
    • 寄生虫
    • 病毒性的
  • 神经病学
  • 肿瘤学

第十二章：生物製药契约製造市场：依公司规模划分

  • 大公司
  • 中小企业

第十三章：生物製药契约製造市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：生物製药契约製造市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：生物製药契约製造市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国生物製药契约製造市场

第十七章：中国生物製药契约製造市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 3P Biopharmaceuticals
  • AbbVie, Inc.
  • Aenova Group GmbH
  • AGC Biologics
  • Ajinomoto Co., Inc.
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Celonic AG
  • FUJIFILM Diosynth Biotechnologies
  • INCOG BioPharma Services, Inc.
  • JRS PHARMA GmbH+Co. KG
  • KBI Biopharma Inc
  • Lonza AG
  • Merck KGaA
  • Pressure BioSciences, Inc. by Emergent Health Corp.
  • ProBioGen AG
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Thermo Fisher Scientific Inc.
  • Toyobo Co., Ltd.
  • WuXi Biologics, Inc.
Product Code: MRR-8C74ADFC15ED

The Biopharmaceuticals Contract Manufacturing Market was valued at USD 23.11 billion in 2025 and is projected to grow to USD 25.23 billion in 2026, with a CAGR of 9.55%, reaching USD 43.79 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 23.11 billion
Estimated Year [2026] USD 25.23 billion
Forecast Year [2032] USD 43.79 billion
CAGR (%) 9.55%

Pioneering Evolution in Biopharmaceutical Contract Manufacturing to Unlock Next Generation Therapeutic Development and Supply Chain Excellence

The contract manufacturing landscape for biopharmaceuticals has evolved from a supplementary service model to a strategic enabler of innovation and speed to market. As therapeutic modalities grow increasingly complex, from monoclonal antibodies to advanced cell and gene therapies, outsourcing partners are no longer mere service providers but critical collaborators in formulation, process optimization, and regulatory compliance. This transformation has been driven by the convergence of advanced technology platforms, stringent quality requirements, and a rising demand for operational flexibility across the development continuum.

Leading biopharmaceutical developers are leveraging partnerships to navigate the intricate balance between cost pressures and the imperative for high-quality output. The reliance on specialized analytical and quality control testing has intensified, while end-to-end biologics manufacturing services have become central to scaling promising drug candidates. Process development and optimization efforts are now pursued in tandem with regulatory authorities to expedite clinical transitions without compromising safety or efficacy.

Against this backdrop, contract manufacturing organizations are positioning themselves as full-spectrum partners capable of supporting both early-stage clinical objectives and high-volume commercial supply. This introduction lays the groundwork for understanding the strategic imperatives shaping the industry and sets the stage for examining the key forces, segmentation insights, and recommendations that follow.

Shifting Paradigms in Biopharmaceutical Contract Manufacturing as Technological Advances and Strategic Collaborations Drive Unprecedented Industry Transformation

The biopharmaceutical contract manufacturing sector is experiencing a profound shift catalyzed by technological breakthroughs, strategic alliances, and changing regulatory paradigms. Single-use technologies and continuous manufacturing approaches are replacing legacy stainless-steel systems, lending agility to production lines and reducing turnaround times. Artificial intelligence and advanced analytics are being integrated into quality control workflows to enhance predictive maintenance and ensure batch consistency.

These advancements coincide with a trend toward personalized medicine, prompting contract manufacturers to develop modular facility designs capable of handling small-batch, high-complexity products alongside traditional biologics. Partnerships between emerging cell and gene therapy innovators and established contract organizations are proliferating, driven by a mutual need for specialized expertise in vector production and cryopreservation protocols.

Simultaneously, regulatory bodies across major markets are issuing guidance that emphasizes process transparency and real-time monitoring. This regulatory evolution has spurred contract providers to adopt digital platforms that facilitate data integrity and compliance tracking. Consequently, the landscape is no longer defined solely by capacity but by the ability to deliver quality outcomes, accelerate timelines, and co-innovate with development partners.

Evaluating the Comprehensive Consequences of the 2025 United States Tariffs on the Biopharmaceutical Contract Manufacturing Supply Chain and Industry Dynamics

The introduction of new United States tariffs in 2025 has generated a ripple effect across the global supply chain for biopharmaceutical contract manufacturing. Raw materials and critical reagents imported from impacted regions are subject to increased duties, leading to elevated input costs and exerting pressure on margin structures. Contract manufacturing organizations have responded by reevaluating supplier portfolios, exploring nearshoring options, and renegotiating long-term supply agreements to buffer against volatility.

Smaller biotechnology firms, which often depend on specialized laboratory reagents and single-use components sourced abroad, find themselves particularly exposed to these cumulative duties. In contrast, larger organizations with diversified supplier networks and in-house formulation capabilities are better positioned to absorb or mitigate the cost burden. Nevertheless, both cohorts are experiencing longer lead times and heightened logistical complexity, underscoring the importance of supply chain resilience.

To alleviate the impact of tariff-driven cost increases, outsourced manufacturing partners are prioritizing process intensification and yield enhancement strategies. By optimizing upstream cell culture conditions and refining downstream purification steps, contract providers can reduce overall material consumption and partially offset higher procurement costs. These measures, combined with strategic inventory management, are essential for maintaining competitiveness in an environment shaped by trade policy shifts.

Revealing Segmentation Insights in Biopharmaceutical Contract Manufacturing across Service and Product Types Production Stages Applications and Organisation Sizes

A granular examination of service type, product type, production stage, application, and organisation size reveals nuanced opportunities and challenges within the contract manufacturing domain. Analytical and quality control testing remains foundational, with emerging emphasis on high-throughput, multi-attribute methods that accelerate decision making. Biologics manufacturing services are evolving to support increasingly complex molecules, while process development and optimization initiatives are being structured as parallel workstreams, enabling faster transitions from bench scale to pilot production.

On the product front, cell and gene therapies demand specialized vector production capabilities, encompassing CAR T therapy workflows and precise gene editing protocols. Monoclonal antibodies continue to benefit from well-established platform processes, whereas recombinant proteins, including enzymes and hormones, leverage optimized expression systems to achieve high yields. Vaccines represent another dynamic segment, with mRNA constructs, protein subunit platforms, and viral vector approaches each requiring distinct manufacturing know-how.

Across clinical and commercial production stages, the industry demonstrates divergent priorities. Phase I through Phase III clinical batches focus on agility and regulatory alignment, whereas commercial manufacturing emphasizes cost efficiencies and scale. Therapeutic applications span autoimmune disorders, cardiovascular diseases, infectious diseases with bacterial, parasitic, and viral strains, neurology, and oncology, each presenting unique quality and safety considerations. Finally, large organisations seek full-service partnerships for end-to-end supply security, while small and medium enterprises often prioritize flexible, project-based engagements to support innovation without heavy capital investment.

Uncovering Regional Dynamics in Biopharmaceutical Contract Manufacturing Spanning the Americas Europe Middle East Africa and Asia Pacific Markets

Regional dynamics play a pivotal role in shaping outsourcing strategies and cost structures. The Americas continue to command significant contract manufacturing capacity, supported by a robust ecosystem of CMOs, regulatory expertise, and established logistics networks. Conversely, Europe, Middle East & Africa benefit from a rich pool of specialized scientific talent, favorable tax incentives in select markets, and a strong tradition of academic-industry collaborations that fuel early-stage bioprocess innovation.

Asia-Pacific has emerged as a growth epicenter, propelled by manufacturing cost arbitrage, government-backed infrastructure investments, and a burgeoning domestic pipeline of biotechnology ventures. Contract providers in this region are expanding capacity to accommodate global demand, introducing state-of-the-art aseptic filling suites and advanced analytics platforms. Simultaneously, regional regulatory authorities are harmonizing standards with international guidelines, simplifying cross-border transfers and bolstering global supply chain integration.

This geographic tapestry underscores the need to align outsourcing decisions with regional strengths. Manufacturing in North America may offer shorter lead times and streamlined regulatory pathways, while partnerships in Europe, Middle East & Africa grant access to specialized services and collaborative research frameworks. Meanwhile, Asia-Pacific is carving out a dual role as both a cost-competitive production hub and a fast-growing market for biologic products, reshaping global capacity dynamics.

Identifying Leading Innovators and Strategic Collaborators Shaping the Future of Biopharmaceutical Contract Manufacturing Worldwide

Leading contract manufacturing organizations have distinguished themselves through technological leadership, capacity footprint, and strategic alliances with both large biopharmaceutical firms and emerging biotech innovators. Several providers have invested heavily in single-use bioreactor systems and continuous chromatography, while others have enhanced their analytical testing suites with multi-attribute mass spectrometry and automated sampling technologies.

Strategic collaborations between CMO partners and academic institutions have accelerated the translation of novel modalities such as gene-edited cell therapies, enabling seamless technology transfer and risk-sharing models. Service providers with modular facility designs offer cost-efficient options for early-stage developers, while those operating mega-scale commercial sites cater to high-volume monoclonal antibody and vaccine production. Additionally, partnerships with reagent manufacturers and equipment suppliers have strengthened supply chain resilience and fostered co-innovation.

The competitive landscape is further shaped by the pursuit of sustainability credentials, with top companies adopting green chemistry principles, carbon-neutral facility operations, and circular single-use plastics recycling programs. These strategic differentiators enhance brand reputation and meet the rising expectations of stakeholders seeking environmentally responsible outsourcing partners.

Actionable Strategies for Industry Leaders to Drive Growth and Operational Excellence in the Evolving Biopharmaceutical Contract Manufacturing Landscape

Industry leaders must adopt a multi-pronged approach to secure resilience and drive growth. Investing in digital platforms that integrate real-time process monitoring with predictive analytics will sharpen decision making and reduce batch failure risks. Flexible manufacturing networks, combining modular facilities and single-use technologies, offer the agility needed to address fluctuating demand profiles across clinical phases and therapeutic modalities.

Formulating collaborative frameworks that incentivize joint process development and shared risk can accelerate time-to-clinic and optimize capital allocation. Leaders should also explore strategic alliances that extend beyond capacity, encompassing co-development partnerships, reagent co-investment, and joint intellectual property arrangements. Diversifying supply chains through geographic dispersion will mitigate tariff impacts and logistical disruptions.

Equally vital is cultivating talent with cross-functional expertise in bioprocess engineering, data science, and regulatory affairs. By fostering a culture that values continuous improvement and open innovation, organizations can maintain operational excellence while adapting to evolving market demands. Embracing sustainability initiatives will further differentiate service offerings and align with corporate social responsibility objectives, ensuring long-term stakeholder value creation.

Methodological Rigor and Innovative Research Techniques Employed to Uncover Critical Insights in Biopharmaceutical Contract Manufacturing Studies

This analysis is grounded in a hybrid research methodology that blends rigorous secondary research with primary qualitative interviews. An extensive review of regulatory guidelines, industry white papers, and proprietary company publications provided the foundational understanding of technological trends and policy shifts. Secondary data sources were vetted for credibility and cross-referenced against recent peer-reviewed journals to ensure factual accuracy.

Complementing this desk research, structured interviews were conducted with C-suite executives, process engineers, regulatory experts, and supply chain managers. These engagements offered nuanced perspectives on strategic imperatives, operational bottlenecks, and partnership models. Triangulation of quantitative and qualitative inputs enabled the identification of high-impact trends and actionable insights.

Key findings were further validated through a collaborative workshop with industry practitioners, where preliminary conclusions were stress-tested against real-world scenarios. This iterative approach ensured that recommendations are both grounded in empirical evidence and aligned with the strategic priorities of today's biopharmaceutical developers and contract manufacturing providers.

Summarizing Key Findings and Synthesizing Insights to Guide Strategic Decision Makers in the Biopharmaceutical Contract Manufacturing Ecosystem

In synthesizing the findings, several core themes emerge: the rising importance of technological agility, the critical role of strategic partnerships, and the necessity of supply chain resilience amid shifting trade policies. These insights underline the imperative for contract manufacturing organizations to transcend traditional capacity-only models and evolve into integrated innovation partners.

Segmentation analysis highlights that while monoclonal antibodies and recombinant proteins maintain established manufacturing platforms, cell and gene therapies and novel vaccine modalities demand bespoke process development expertise. Regional dynamics signal that Asia-Pacific is poised for rapid expansion, whereas Europe, Middle East & Africa will continue to offer strategic centers of excellence in early-stage development.

For decision makers, the convergence of digitalization, sustainability demands, and evolving tariff landscapes mandates a holistic strategy. By aligning service portfolios with emerging product trends, diversifying geographic footprints, and investing in cutting-edge process technologies, organizations can position themselves for long-term success. The insights presented serve as a blueprint for navigating the next chapter of biopharmaceutical contract manufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopharmaceuticals Contract Manufacturing Market, by Service Type

  • 8.1. Analytical & Quality Control Testing
  • 8.2. Biologics Manufacturing Service
  • 8.3. Process Development & Optimization

9. Biopharmaceuticals Contract Manufacturing Market, by Product Type

  • 9.1. Cell And Gene Therapy
    • 9.1.1. CAR T Therapy
    • 9.1.2. Gene Editing Therapy
  • 9.2. Monoclonal Antibodies
  • 9.3. Recombinant Proteins
    • 9.3.1. Enzymes
    • 9.3.2. Hormones
  • 9.4. Vaccines
    • 9.4.1. mRNA Vaccines
    • 9.4.2. Protein Subunit Vaccines
    • 9.4.3. Viral Vector Vaccines

10. Biopharmaceuticals Contract Manufacturing Market, by Production Stage

  • 10.1. Clinical
    • 10.1.1. Phase I
    • 10.1.2. Phase II
    • 10.1.3. Phase III
  • 10.2. Commercial

11. Biopharmaceuticals Contract Manufacturing Market, by Application

  • 11.1. Autoimmune Disorders
  • 11.2. Cardiovascular
  • 11.3. Infectious Diseases
    • 11.3.1. Bacterial
    • 11.3.2. Parasitic
    • 11.3.3. Viral
  • 11.4. Neurology
  • 11.5. Oncology

12. Biopharmaceuticals Contract Manufacturing Market, by Organisation Size

  • 12.1. Large Organisation
  • 12.2. Small & Medium Organisation

13. Biopharmaceuticals Contract Manufacturing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biopharmaceuticals Contract Manufacturing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biopharmaceuticals Contract Manufacturing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biopharmaceuticals Contract Manufacturing Market

17. China Biopharmaceuticals Contract Manufacturing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 3P Biopharmaceuticals
  • 18.6. AbbVie, Inc.
  • 18.7. Aenova Group GmbH
  • 18.8. AGC Biologics
  • 18.9. Ajinomoto Co., Inc.
  • 18.10. Aurobindo Pharma Limited
  • 18.11. Boehringer Ingelheim International GmbH
  • 18.12. Cambrex Corporation
  • 18.13. Catalent, Inc.
  • 18.14. Celonic AG
  • 18.15. FUJIFILM Diosynth Biotechnologies
  • 18.16. INCOG BioPharma Services, Inc.
  • 18.17. JRS PHARMA GmbH + Co. KG
  • 18.18. KBI Biopharma Inc
  • 18.19. Lonza AG
  • 18.20. Merck KGaA
  • 18.21. Pressure BioSciences, Inc. by Emergent Health Corp.
  • 18.22. ProBioGen AG
  • 18.23. Rentschler Biopharma SE
  • 18.24. Samsung Biologics
  • 18.25. Thermo Fisher Scientific Inc.
  • 18.26. Toyobo Co., Ltd.
  • 18.27. WuXi Biologics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CAR T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CAR T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CAR T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GENE EDITING THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GENE EDITING THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GENE EDITING THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARASITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY LARGE ORGANISATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY LARGE ORGANISATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY LARGE ORGANISATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL & MEDIUM ORGANISATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL & MEDIUM ORGANISATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL & MEDIUM ORGANISATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 205. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 206. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 207. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 208. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 210. GCC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 238. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 239. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 240. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 241. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 243. G7 BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 249. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 250. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 251. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 252. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 254. NATO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERA